Skip to content

Is the SCYNEXIS stock sell off creating a value opportunity?


Pharma stocks can be volatile, especially in the sub-$100m market cap space. Shares in fungal treatments specialist SCYNEXIS [NASDAQ:SCYX] fell off a cliff in September, dropping from $3.45 to hit $1.71 at time of writing. What caused the sell off, and does SCYNEXIS now represent a buying opportunity, or should investors be looking at close peer Aquesitive Therapeutics [NASDAQ:AQST] instead?

The big sell off first: this seems to have occurred when SCYNEXIS issued a voluntary nationwide recall of two lots of its Brexafemme tablets, available at the consumer level, due to potential cross-contamination with a non-bacterial drug substance in the citrate used to manufacture the tablets. The company thought the problem had the potential to create hypersensitivity reactions in patients.

SCYNEXIS had to move to recall the product down to the consumer level. This is never good news for drug companies, even when they are moving with the best of intentions. It led many investors to hit the sell button, but currently the company is still sitting on some solid fundamentals, and there is a case to argue that $1.71 may be too cheap. The PE ratio is down at 1.8X with an EBITDA of 45.82%.

Want the full story? Access all of The Armchair Trader's content for just £5.99 per month.

Get weekly investment ideas and tips that will take your investing to the next level. Sign up here.

Free 28 day trial. Cancel anytime.

Log In or Sign Up to Armchair Trader+

Already a member? Log in here:

Not a member yet? Sign up for your free trial or check out the benefits of membership.

Further content of this article is not available as it is for members only. Please visit the registration page for Armchair Trader Plus+ for further details on the benefits of becoming a member.

Like this article? Sign up to our free newsletter.

This article does not constitute investment advice. Do your own research or consult a professional advisor.

'How to' Guides

Our latest in-depth company reports

Detailed reviews of selected companies and investment trusts.

On the podcast

Sign up for great investing stock tips

Thanks to our Partners

Our partners are established, regulated businesses and we are grateful for their support.

FP Markets
CME Group
Back To Top